Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Protocol: Neoadjuvant Docetaxel with Trastuzumab and Pertuzumab in HER2 + Breast Cancer
In the neoCARHP trial, the THP regimen was found to be noninferior to TCbHP in terms of pathologic complete response rates but had fewer grade 3 or higher adverse events. The omiss
New Reference: Toripalimab with Chemotherapy for Advanced Esophageal SCC
In the JUPITER-06 trial, toripalimab combined with chemotherapy significantly improved overall and progression-free survival in patients with advanced esophageal squamous cell carc
New Reference: Temozolomide for Anaplastic Glioma
The CATNON trial demonstrated a survival benefit with adjuvant temozolomide in patients with IDH-mutated astrocytoma compared to radiotherapy alone. Concurrent temozolomide did not
New Protocol: Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Metastatic Breast Cancer
ASCENT-04 phase 3 trial showed that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival compared to chemotherapy plus pembrolizumab in patient
New Protocol: Lenvatinib with Bevacizumab for Gynecological Clear Cell Carcinoma
In this phase 2 trial of pembrolizumab plus lenvatinib in patients with recurrent gynaecological clear cell carcinoma, the combination of lenvatinib and pembrolizumab showed a 40%
New Protocol: Letrozole and Palbociclib with Trastuzumab and Pertuzumab for Neoadjuvant Triple-Positive Breast Cancer
The TOUCH trial showed that palbociclib and letrozole combined with dual anti-HER2 therapy achieved similar pCR rates to paclitaxel in HR-positive/HER2-positive early breast cancer
New Reference: Palbociclib Addition to Maintenance Therapy in Triple-Positive Breast Cancer
The addition of palbociclib to maintenance anti-HER2 and endocrine therapies significantly improved progression-free survival in patients with hormone-receptor-positive, HER2-posit
New Reference: Olaparib for PALB2 or BRCA1/2 Mutated Breast Cancer
The phase II TBCRC 048 study found olaparib to be effective in metastatic breast cancer patients with germline PALB2 or somatic BRCA1/2 mutations. The overall response rate was sig
New Protocol: Ultra-Low Dose Nivolumab for Advanced Solid Tumors
Ultra-low-dose nivolumab significantly improved overall survival compared to chemotherapy in patients with relapsed refractory solid tumors while reducing severe toxicities. The re
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.